Skip to content
Tradjenta, Trajenta(linagliptin)
Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy (linagliptin) is a small molecule pharmaceutical. Linagliptin was first approved as Tradjenta on 2011-05-02. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Tradjenta (generic drugs available since 2021-08-30)
Combinations
Glyxambi, Jentadueto, Trijardy (generic drugs available since 2021-08-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Empagliflozin
+
Linagliptin
Tradename
Company
Number
Date
Products
GLYXAMBIBoehringer IngelheimN-206073 RX2015-01-30
2 products, RLD, RS
Empagliflozin
+
Linagliptin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
TRIJARDY XRBoehringer IngelheimN-212614 RX2020-01-27
4 products, RLD, RS
Linagliptin
Tradename
Company
Number
Date
Products
TRADJENTABoehringer IngelheimN-201280 RX2011-05-02
1 products, RLD, RS
Linagliptin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
JENTADUETOBoehringer IngelheimN-201281 RX2012-01-30
3 products, RLD, RS
JENTADUETO XRBoehringer IngelheimN-208026 RX2016-05-27
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
glyxambiNew Drug Application2021-06-17
jentaduetoNew Drug Application2022-04-27
tradjentaNew Drug Application2022-10-14
trijardy xrNew Drug Application2021-06-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
EMPAGLIFLOZIN / LINAGLIPTIN, GLYXAMBI, BOEHRINGER INGELHEIM
2023-03-30M-252
LINAGLIPTIN, TRADJENTA, BOEHRINGER INGELHEIM
2023-03-30M-252
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM
2023-03-30M-252
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM
2023-03-30M-252
Patent Expiration
Patent
Expires
Flag
FDA Information
Empagliflozin / Linagliptin, Glyxambi, Boehringer Ingelheim
99499982034-06-11U-2290, U-2731
102586372034-04-03U-2290, U-2731
110903232034-04-03U-3191, U-3192
85519572029-10-14DPU-1651, U-2730
75794492028-08-01DP
86739272027-05-04U-1503, U-1652
91738592027-05-04DPU-1503, U-1772
110335522027-05-04DP
77139382027-04-15DS, DP
88838052025-11-26DP
74079552025-05-02DS, DP
81196482023-08-12U-774, U-802, U-1270, U-1651, U-1652
81785412023-08-12U-775, U-1244, U-1245, U-1270, U-1652, U-1653, U-1654, U-1853
Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim
95550012033-03-06DPU-1967, U-1968
Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim
105961202032-03-07DPU-2776, U-2790
115648862032-03-07DPU-3531
104061722030-06-15DPU-2733
91557052030-05-21DP
94150162029-04-02DP
100223792029-04-02U-2339, U-2732
Linagliptin, Tradjenta, Boehringer Ingelheim
88531562031-03-05U-1642
88466952030-06-04U-1503
94865262029-08-05U-1915
100348772029-08-05U-2347
Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim
109738272029-04-02DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD11: Metformin and linagliptin
— A10BD19: Linagliptin and empagliflozin
— A10BD27: Metformin, linagliptin and empagliflozin
— A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
— A10BH05: Linagliptin
HCPCS
No data
Clinical
Clinical Trials
166 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E115840231591
Insulin resistanceD007333EFO_0002614—122—5
Prediabetic stateD011236EFO_1001121R73.03——2215
Diabetes mellitusD003920EFO_0000400E08-E131—12—4
Glucose intoleranceD018149HP_0000833R73.03—1—1—2
SchizophreniaD012559EFO_0000692F201——1—2
Diabetic nephropathiesD003928EFO_0000401———1—1
Peritoneal dialysisD010530———1—1
Coronavirus infectionsD018352EFO_0007224B34.2———1—1
Coronary artery diseaseD003324I25.1———1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Glucose metabolism disordersD044882—11——2
Covid-19D000086382U07.1——2——2
AlbuminuriaD000419EFO_0004285R80.9—11——2
Left ventricular dysfunctionD018487——2——2
HyperglycemiaD006943HP_0003074R73.9——1——1
Severe acute respiratory syndrome-related coronavirusD045473NCBITaxon_227859——1——1
Sars-cov-2D000086402——1——1
Respiratory tract diseasesD012140——1——1
CoronavirusD017934——1——1
Metabolic syndromeD024821EFO_0000195E88.81——1——1
Show 1 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N1911———2
Non-small-cell lung carcinomaD00228911———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—44————44
HypertensionD006973EFO_0000537I102————2
Hepatic insufficiencyD0485501————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.0————11
Type 1 diabetes mellitusD003922EFO_0001359E10————11
Chronic renal insufficiencyD051436N18————11
Cardiovascular diseasesD002318EFO_0000319I98————11
Cognitive dysfunctionD060825G31.84————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLINAGLIPTIN
INNlinagliptin
Description
Linagliptin is a xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. It has a role as an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor and a hypoglycemic agent. It is a member of quinazolines and an aminopiperidine. It is functionally related to a 7H-xanthine.
Classification
Small molecule
Drug classdipeptidyl aminopeptidase-IV inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Identifiers
PDB2RGU
CAS-ID668270-12-0
RxCUI1100699
ChEMBL IDCHEMBL237500
ChEBI ID68610
PubChem CID10096344
DrugBankDB08882
UNII ID3X29ZEJ4R2 (ChemIDplus, GSRS)
Target
Agency Approved
DPP4
DPP4
Organism
Homo sapiens
Gene name
DPP4
Gene synonyms
ADCP2, CD26
NCBI Gene ID
1803
Protein name
dipeptidyl peptidase 4
Protein synonyms
ADABP, ADCP-2, Adenosine deaminase complexing protein 2, CD26, Dipeptidyl peptidase IV, dipeptidylpeptidase 4, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2), DPP IV, Gly-Pro naphthylamidase, Post-proline dipeptidyl aminopeptidase IV, T-cell activation antigen CD26, TP103, Xaa-Pro-dipeptidylaminopeptidase
Uniprot ID
Q53TN1
Mouse ortholog
Dpp4 (13482)
dipeptidyl peptidase 4 (P28843)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Trajenta - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,235 documents
View more details
Safety
Black-box Warning
Black-box warning for: Jentadueto, Trijardy xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,203 adverse events reported
View more details